Francesca Bruce

Francesca Bruce

Senior Writer

Newcastle, UK

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest from Francesca Bruce

Advanz Pharma’s Ocaliva Loses EU Conditional Marketing Authorization

Advanz Pharma, the company that markets Ocaliva for primary biliary cholangitis in the EU, will continue to supply the drug on a compassionate use or named patient basis.

Canada’s New Pharmacare Committee “Excludes” Industry

As mandated by the recent Pharmacare Act in Canada, a new committee will make recommendations on how Canada can provide universal drug coverage to it citizens.

Canada’s Data Linkage Roadmap To Drive Decision Making For Rare Disease Drugs

The roadmap sets out eight steps to help registry teams link data from registry records with administrative health services data.

Transnational Collaborative Health Tech Assessments Have Much To Offer

European cross-border HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, say Nordic health technology assessment experts. Talks on HTA collaborations outside Europe are also underway.

Nordic Medtech Experts Urge More Collaboration On Health Technology Assessments

European cross-country HTA collaborations have much to learn from each other to keep prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.

EU HTA Reg: CoI Rules Limit Participation Of Experts In Joint Clinical Assessments

The European Commission has now adopted the third implementing act for the Health Technology Assessment Regulation. This sets out rules for managing conflicts of interest of anyone involved in joint clinical assessments or joint scientific consultations under the regulation.